Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414525 | 0.92 | HCRTR2 (0.41) | HCRTR2POLBALDH1A1CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6414520 | 0.92 | HCRTR2 (0.41) | HCRTR2POLBALDH1A1CTSBCTSS | |
| SCHEMBL6410165 | 0.90 | HCRTR2 (0.41) | HCRTR2POLBALDH1A1MAPTGAA | |
| SCHEMBL6411012 | 0.90 | HCRTR2 (0.41) | HCRTR2CYP3A4POLBALDH1A1CTSB | |
| Hydrochloric Acid SCHEMBL5249454 | 0.89 | HCRTR2 (0.41) | HCRTR2POLBALDH1A1MAPTGAA | |
| SCHEMBL5255921 | 0.89 | CCR5 (0.38) | HCRTR2CYP3A4POLBALDH1A1NAMPT | |
| SCHEMBL6417456 | 0.88 | CTSS (0.37) | CTSBCTSSCTSKSCN9A | |
| SCHEMBL5417145 | 0.87 | CYP3A4 (0.38) | HCRTR2CYP3A4POLBSCN9ANAMPT | |
| Hydrochloric Acid SCHEMBL6410061 | 0.87 | HCRTR2 (0.42) | HCRTR2POLBALDH1A1CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6409408 | 0.87 | HCRTR2 (0.41) | HCRTR2POLBALDH1A1CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | HCRTR2 247/4885CYP3A4 2122/4885POLB 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.